| Drug Name: | Dactinomycin (50-76-0) |
|---|---|
| PubChem ID: | 44415057 |
| SMILES: | C[C@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C |
| InchiKey: | RJURFGZVJUQBHK-GIUPLMLQSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antineoplastic Agents, Enzyme Inhibitors, Nucleic Acid Synthesis Inhibitors, Protein Synthesis Inhibitors |
| Molecular Weight (dalton) | : | 1255.43 |
| LogP | : | 0.72564 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 18 |
| Hydrogen Bond Donor Count | : | 5 |
| Total Polar Surface Area | : | 359.98 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Angiogenesis | Urokinase-type plasminogen activator (P00749) | OSM stimulated increased mRNA levels of urokinase-plasminogen activator (uPA) and urokinase-plasminogen activator receptor (uPAR) in a time and dose-dependent manner,which supports a role for OSM in modulating the different phases of angiogenesis [ ADR Type 1 ] | Induction of the urokinase plasminogen activator system by oncostatin M promotes endothelial migration |
| Cytotoxicity | Hyaluronidase (Q12794) | Binding and Western-blotting analyses revealed that hyaluronidase downregulated the intra-TBP@suggestting that serum fetuin and intraTBP are involved in the hyaluronidase induction of TNF/ ActD resistance@which makes fibrosarcoma cells resistant to tumor necrosis factor and Fas cytotoxicity [ ADR Type 2 ] | Hyaluronidase induces murine L929 fibrosarcoma cells resistant to tumor necrosis factor and Fas cytotoxicity in the presence of actinomycin D |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category